美国ApexBio抑制剂等活性小分子化合物

 

美国ApexBio公司是由哈佛博士后团体于2008年成立,专注于为全球科研工作者定制复杂和不稳定的活性小分子。目前已经积累了6000多种高纯度活性小分子,涉及肿瘤、表观遗传学、神经学、凋亡、氧化性损伤、内分泌学等研究领域。...

 

订购方式

 

全国免费服务热线:4006-111-945

邮件订货:sales@fansbio.com

QQ:39198264

网站:http://www.fansbio.com

地址:广东省广州市天河区车陂路95号瑞星大酒店336房

 

部分抑制剂产品

A8882 THZ1 CDK7 inhibitor 
A8815 SM-164 cIAP-1, cIAP-2 and XIAP inhibitor
A8191 Nanaomycin A DNMT3B inhibitor
A8802 (S)-Crizotinib MTH1 inhibitor
A8889 G-749 FLT3 inhibitor
A1910 Bromodomain Inhibitor, (+)-JQ1 BET bromodomain inhibitor
A2606 Epoxomicin 20S proteasome inhibitor
A1901 Q-VD-Oph pan-caspase inhibitor
A1902 Z-VAD-FMK pan-caspase inhibitor
A1337 U0126-EtOH MEK1/2 inhibitor
A1402 Gemcitabine HCl inhibits DNA synthesis
A1663 PD98059 Inhibitor of MKK/MEK.
A1723 Roscovitine (Seliciclib,CYC202) potent CDK inhibitor
A1792 PD184352 (CI-1040) selective MEK inhibitor
A1805 Imatinib Mesylate (STI571) Multi-target kinase inhibitor of abl, c-kit, and PDGFR
A1832 Doxorubicin (Adriamycin) Antitumor antibiotic agent
A1877 XAV-939 Tankyrase inhibitor
A2067 PI-103 PI3K, DNA-PK, and mTOR inhibitor
A2133 Saracatinib (AZD0530) Dual inhibitor of Src and Abl
A2149 Bosutinib (SKI-606) potent dual c-Src/Abl inhibitor
A2585 MG-132 Cell permeable, reversible proteasome inhibitor
A2614 Bortezomib (PS-341) Cell-permeable proteasome inhibitor
A2974 Foretinib (GSK1363089) Flt-1, Flt-4, Met, and Ron inhibitor.
A2977 Cabozantinib (XL184, BMS-907351) c-Met, VEGFR2, and RET inhibitor
A3001 Ibrutinib (PCI-32765) Bruton's tyrosine kinase (BTK) inhibitor
A3002 Veliparib (ABT-888) Potent inhibitor of PARP-1 and PARP-2
A3003 Enzalutamide (MDV3100) Potent androgen receptor antagonist
A3004 Vemurafenib (PLX4032, RG7204) Potent and selective inhibitor of BRAF with V600E mutation
A3005 CAL-101 (Idelalisib, GS-1101) Cell-permeable PI3K inhibitor
A3007 ABT-263 (Navitoclax) Potent Bcl-2 family inhibitor
A3008 Y-27632 2HCl p160ROCK inhibitor
A3010 MK-2206 2HCl Akt inhibitor
A3011 CHIR-99021 (CT99021) HCl Cell-permeable, ATP-competitive GSK-3 inhibitor
A3012 Ruxolitinib (INCB018424) Janus kinase inhibitor 
A3013 PD0325901 A selective and non ATP-competitive MEK inhibitor
A3014 BGJ398 (NVP-BGJ398) FGFR inhibitor 
A3015 BKM120 (NVP-BKM120, Buparlisib) PI3K inhibitor
A3016 PLX-4720 Potent and selective inhibitor of BRAF with V600E mutation
A3017 Dasatinib Potent Abl and Src kinases inhibitor
A3018 Trametinib (GSK1120212) Potent and selective MEK1 and MEK2 inhibitor
A3020 Crizotinib (PF-02341066) Potent c-MET and ALK inhibitor
A3021 Vismodegib (GDC-0449) Hedgehog antagonist 
A3022 Pazopanib HCl (GW786034 HCl) Multi-target kinase inhibitor, inhibits VEGFR, PDGFR, and FGFR
A3432 GDC-0941 orally bioavailable and selective class I PI3K inhibitor 
A3965 BI 2536 PLK1 inhibitor
A4005 RO4929097 γ secretase inhibitor
A4054 17-AAG (Tanespimycin) Potent inhibitor of chaperone protein Hsp90
A4057 AUY922 (NVP-AUY922) Hsp90 inhibitor
A4084 Vorinostat (SAHA, MK0683) Class I and II HDAC inhibitor
A4089 Mocetinostat (MGCD0103) Class I selective HDAC inhibitor
A4110 Alisertib (MLN8237) Potent and selective Aurora A Kinase inhibitor
A4111 VX-680 (Tozasertib, MK-0457) Aurora inhibitor
A4112 Barasertib (AZD1152-HQPA) Potent and selective Aurora Kinase B inhibitor
A4135 Tofacitinib (CP-690550) Citrate Potent JAK inhibitor
A4137 AZD1480 ATP-competitive JAK2 inhibitor
A4154 Olaparib (AZD2281, Ku-0059436) Potent PARP inhibitor
A4156 Rucaparib (AG-014699,PF-01367338) Potent PARP inhibitor
A4180 SRT1720 SIRT1 activator
A4194 Obatoclax Mesylate (GX15-070) antagonist of Bcl-2 
A4211 Lenalidomide (CC-5013) Antitumor compound, inhibits angiogenesis
A4221 YM155 (Sepantronium Bromide) Survivin suppressor, induces apoptosis
A4393 Paclitaxel Chemotherapy agent
A4604 SP600125 JNK1/2/3 inhibitor
A4605 KU-55933 (ATM Kinase Inhibitor) Potent and selective ATM inhibitor
A5467 Ponatinib (AP24534) pan-BCR-ABL inhibitor
A5639 BIRB 796 (Doramapimod) Cell pemeable p38 MAP Kinase Inhibitor 
A5919 AZD7762 inhibitor of checkpoint kinases (Chks) 
A8167 Rapamycin (Sirolimus) mTOR inhibitor
A8169 Everolimus (RAD001) mTOR inhibitor
A8171 Entinostat (MS-275) HDAC1 and HDAC3 but not HDAC8 inhibitor
A8178 Panobinostat (LBH589) Broad spectrum HDAC inhibitor
A8183 Trichostatin A (TSA) HDAC inhibitor
A8192 Staurosporine potent, cell permeable PKC inhibitor 
A8193 ABT-737 Cell-permeable Bcl-2 inhibitor
A8200 DAPT (GSI-IX) γ-secretase inhibitor
A8207 Selumetinib (AZD6244) Potent, selective, and ATP-uncompetitive MEK inhibitor
A8214 AZD8055 Potent, selective, and ATP-competitive mTOR inhibitor
A8217 ICG-001 Wnt/β-catenin pathway inhibitor
A8219 Gefitinib (ZD1839) Selective EGFR inhibitor
A8232 Nilotinib (AMN-107) Bcr-Abl tyrosine kinase inhibitor
A8234 Erlotinib HCl (OSI-744) Selective EGFR inhibitor
A8236 Regorafenib (BAY 73-4506) VEGFR, PDGFR, FGFR, mutant kit, RET, and Raf-1 inhibitor
A8245 Sorafenib Tosylate Raf kinases and tyrosine kinases inhibitor
A8246 BEZ235 (NVP-BEZ235, Dactolisib) dual inhibitor of PI3K and mTOR 
A8247 Afatinib (BIBW2992) Irreversible EGFR and HER2 inhibitor
A8249 SB431542 TGF-βR1 (ALK5) inhibitor
A8250 LY294002 PI3K inhibitor
A8251 TAE684 (NVP-TAE684) Potent and selective ALK inhibitor
A8252 Nintedanib (BIBF 1120) VEGFR, PDGFR, and FGFR inhibitor
A8309 Perifosine (KRX-0401) AKT inhibitor
A8314 Temsirolimus (CCI-779, NSC 683864) mTOR inhibitor
A8315 NU7441 (KU-57788) DNA-PK inhibitor
A8316 Palbociclib (PD-0332991) HCl Highly selective CDK4/6 inhibitor
A8321 Cisplatin A broad-spectrum chemotherapeutic agent
A8334 OSI-906 (Linsitinib) Dual inhibitor of IGF1R and IR
A8338 S3I-201 STAT3 inhibitor
A8340 Cyclopamine Smoothened inhibitor
A8370 Axitinib VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit inhibitor
A8546 R406 ATP-competitive Syk inhibitor
A8548 Fingolimod (FTY720) HCl A potent S1P receptor agonist
A8553 Ataluren (PTC124) selective ribosomal read-through of premature inducer
A8555 Vandetanib (ZD6474) potent VEGFR2 inhibitor 
B1045 Sunitinib Malate An oral, multi-targeted and small-molecule RTK inhibitor
B1285 SB203580 A specific p38 MAPK inhibitor
B1407 Dabrafenib (GSK2118436) mutant BRAFV600 specific inhibitor